MRNA
MARINA BIOTECH INC COM STK (DE)MRNA
MRNA
Delisted
MRNA was delisted on the 1st of February, 2012.
Financial journalist opinion
Neutral
Accesswire
1 day ago
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for individuals aged six months and older. Moderna is on track to deliver the updated vaccine in time for the 2025-2026 vaccination season.
Neutral
Accesswire
2 days ago
Moderna to Present at Upcoming Conferences in September 2025
CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences: Morgan Stanley's 23rd Annual Global Healthcare Conference, on Monday, September 8th at 10:00am ET Bernstein Insights: Healthcare Leaders and Disruptors, on Thursday, September 25th at 10:30am ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website. investors.modernatx.com.
Positive
Investors Business Daily
5 days ago
6 Battered S&P 500 Stocks Blow Away Nvidia In 'Healthy Rotation'
Getting tired of the same old S&P 500 stocks, like Nvidia, dominating markets? Some beat-up stocks are rallying in what looks like a shift.
Positive
The Motley Fool
6 days ago
If You're in Your 30s, Consider Buying These 2 Healthcare Stocks
Investing styles tend to evolve as people age. Seniors who are already retired often look for steady, reliable, dividend-paying companies.
Neutral
Benzinga
1 week ago
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
Pfizer Inc.'s PFE COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna Inc. MRNA to step in to help fill potential gaps.
Neutral
The Motley Fool
1 week ago
The 3 Things That Matter for Moderna Now
Since hitting their peak in late 2021, Moderna's (MRNA -1.69%) shares are down by more than 90%. The biotech company gained recognition by developing one of the leading coronavirus vaccines on the market, but its revenue and earnings subsequently plummeted as the pandemic waned.
Negative
Market Watch
2 weeks ago
Moderna's stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals
Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the biotechnology company's vaccines and said it would cancel some contracts and stop funding mRNA drug development.
Negative
Seeking Alpha
2 weeks ago
Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish
Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. MRNA stock has plummeted over 70% in the past year, reflecting investor concerns about ongoing losses and limited COVID vaccine demand. Despite recent approval of mNEXSPIRE, guidance suggests heavy 2025 losses, with management focused on downsizing and cost control.
Positive
Zacks Investment Research
3 weeks ago
Here's What Key Metrics Tell Us About Moderna (MRNA) Q2 Earnings
Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neutral
Fast Company
3 weeks ago
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Charts implemented using Lightweight Charts™